How big is DarioHealth Corp.?

As of Jun 18, DarioHealth Corp. has a market capitalization of 30.72 million, with net sales of 28.02 million and a net profit of -32.31 million over the latest four quarters. Shareholder's funds are reported at 72.02 million, and total assets amount to 118.88 million.

As of Jun 18, DarioHealth Corp. has a market capitalization of 30.72 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 28.02 million, while the sum of net profit for the same period is -32.31 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 72.02 million, and total assets amount to 118.88 million.

What does DarioHealth Corp. do?

DarioHealth Corp. is a Digital Therapeutics company focused on integrated digital therapeutic interventions in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $7 million and a net loss of $9 million, with a market cap of $30.72 million.

Overview:<BR>DarioHealth Corp. is a Digital Therapeutics (DTx) company operating in the Pharmaceuticals & Biotechnology industry, focusing on integrated digital therapeutic interventions.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 7 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 30.72 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.02 <BR>Return on Equity: -48.75% <BR>Price to Book: 0.42 <BR><BR>Contact Details:<BR>Address: 8 Hatokhen St., CAESAREA None : 38900 <BR>Tel: 972 3 6222929 <BR>Fax: 972 4 7704059 <BR>Website: http://mydario.com

Should I buy, sell or hold DarioHealth Corp.?

Who are in the management team of DarioHealth Corp.?

As of March 2022, the management team of DarioHealth Corp. includes Yoav Shaked (Independent Chairman), Erez Raphael (CEO), and several directors: Dennis Matheis, Adam Stern, Allen Kamer, Hila Karah, and Dennis McGrath. They are responsible for the company's strategic direction and governance.

As of March 2022, the management team of DarioHealth Corp. includes the following individuals:<BR><BR>- Mr. Yoav Shaked, Independent Chairman of the Board<BR>- Mr. Erez Raphael, Chief Executive Officer and Director<BR>- Dennis Matheis, Director<BR>- Mr. Adam Stern, Director<BR>- Mr. Allen Kamer, Independent Director<BR>- Ms. Hila Karah, Independent Director<BR>- Mr. Dennis McGrath, Independent Director<BR><BR>This team oversees the strategic direction and governance of the company.

Is DarioHealth Corp. overvalued or undervalued?

DarioHealth Corp. is considered a risky investment due to its significant losses and negative valuation metrics, including a Price to Book Value of 0.42 and an EV to EBITDA of -0.80, which contribute to its underperformance of -60.76% year-to-date compared to the S&P 500's 12.22%.

As of 11 May 2016, the valuation grade for DarioHealth Corp. changed from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its significant losses and negative valuation metrics. Key ratios include a Price to Book Value of 0.42, an EV to EBIT of -0.67, and an EV to EBITDA of -0.80, all of which reflect a concerning financial position.<BR><BR>In comparison to peers, DarioHealth Corp. has a less favorable EV to EBITDA ratio than Clearpoint Neuro, Inc. (-14.42) and Stereotaxis, Inc. (-11.42), both of which are also classified as risky but show less severe negative metrics. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -60.76% compared to the index's 12.22%, reinforcing the notion that the stock is overvalued.

Is DarioHealth Corp. technically bullish or bearish?

As of September 8, 2025, DarioHealth Corp. shows a mildly bullish trend due to monthly indicators, despite bearish signals from weekly and daily analyses, and has underperformed the S&P 500 significantly with a year-to-date return of -60.76%.

As of 8 September 2025, the technical trend for DarioHealth Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the monthly MACD and KST indicators, which are both mildly bullish. However, the weekly MACD, Bollinger Bands, and Dow Theory indicate bearish conditions, suggesting a mixed outlook. The daily moving averages are also bearish, adding to the overall caution. <BR><BR>In terms of performance, DarioHealth has significantly underperformed the S&P 500 across all observed periods, with a year-to-date return of -60.76% compared to the S&P 500's 12.22%, and a one-year return of -65.72% versus the S&P 500's 17.14%.